Supriya Lifescience Delivers Strong Q2 FY26 Performance with 20.3% YoY Revenue Growth

Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing, has reported a 20.3% year-over-year growth in Revenue to Rs 199.83 crore in Q2 FY26. The EBITDA for Q2 FY26 stood at Rs 72.65 crore, with an EBITDA margin of 36.4%. The Profit After Tax (PAT) for Q2 FY26 was Rs 50.43 crore, with a PAT Margin of 25.2%. The anesthetic segment led the revenue growth, contributing 54% to the revenue. European markets continue to lead with a contribution of 37% of the business revenue in Q2 FY26. The company has acquired three separate land parcels near different plants to support the future growth of various business segments.